Literature DB >> 2525100

Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes.

L L Lanier1, J H Phillips, R Testi.   

Abstract

CD16 is an IgG Fc receptor that is predominantly expressed on human natural killer (NK) cells and granulocytes. The CD16 antigen expressed on neutrophils is a 50 to 70-kDa glycoprotein attached to the plasma membrane by a phosphatidylinositol-glycan linkage that is susceptible to cleavage by phosphatidylinositol-specific phospholipase C (PIPLC). By contrast, treatment of NK cells with PIPLC did not cleave CD16 from the cell surface. Biochemical analysis of the deglycosylated CD16 revealed a substantial difference in the core polypeptides expressed by NK cells and granulocytes. Culture of radiolabeled NK cells resulted in the spontaneous release of a CD16 molecule, smaller than the membrane form of CD16. These findings demonstrate that structural differences exist in the CD16 antigens expressed on NK cells and granulocytes that may potentially influence their functional activities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525100     DOI: 10.1002/eji.1830190431

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Adhesion and activation molecules expressed by human natural killer cells.

Authors:  A Santoni; A Gismondi; R Paolini; A Procopio; S Morrone; F Mainiero; G Santoni; M Piccoli; L Frati
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  Altered expression of Fc gammaRIII (CD16) on polymorphonuclear neutrophils from individuals with human immunodeficiency virus type 1 disease and pulmonary tuberculosis.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

3.  Soluble Fc gamma receptor III in human plasma originates from release by neutrophils.

Authors:  T W Huizinga; M de Haas; M Kleijer; J H Nuijens; D Roos; A E von dem Borne
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

Review 4.  Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.

Authors:  Jianming Wu; Hemant K Mishra; Bruce Walcheck
Journal:  J Leukoc Biol       Date:  2019-02-20       Impact factor: 4.962

5.  Identification of high-affinity anti-CD16A allotype-independent human antibody domains.

Authors:  Wei Li; Hongjia Yang; Dimiter S Dimitrov
Journal:  Exp Mol Pathol       Date:  2016-10-03       Impact factor: 3.362

6.  Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.

Authors:  Jennifer T Grier; Lisa R Forbes; Linda Monaco-Shawver; Jennifer Oshinsky; T Prescott Atkinson; Curtis Moody; Rahul Pandey; Kerry S Campbell; Jordan S Orange
Journal:  J Clin Invest       Date:  2012-09-24       Impact factor: 14.808

Review 7.  Functional regulation of human neutrophil Fc gamma receptors.

Authors:  Periasamy Selvaraj; Nimita Fifadara; Shanmugam Nagarajan; Ashley Cimino; Guixian Wang
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  Phenotypic analysis of a resting subpopulation of human peripheral blood NK cells: the FcR gamma III (CD16) molecule and NK cell differentiation.

Authors:  H S Warren; L J Skipsey
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

9.  Channel catfish soluble FcmuR binds conserved linear epitopes present on Cmu3 and Cmu4.

Authors:  Deepak K Nayak; Aihua Tang; Melanie Wilson; Norman W Miller; Eva Bengtén
Journal:  Mol Immunol       Date:  2009-12-23       Impact factor: 4.407

10.  Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Authors:  S D Voss; R J Robb; G Weil-Hillman; J A Hank; K Sugamura; M Tsudo; P M Sondel
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.